Baha 5 Super Power Sound Processor

K153245 · Cochlear Americas · LXB · Mar 2, 2016 · Ear, Nose, Throat

Device Facts

• Record ID: K153245
• Device Name: Baha 5 Super Power Sound Processor
• Applicant: Cochlear Americas
• Product Code: LXB · Ear, Nose, Throat
• Decision Date: Mar 2, 2016
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 874.3302
• Device Class: Class 2
• Attributes: Therapeutic, Pediatric

Intended Use

The Cochlear™ Baha® 5 SuperPower Sound Processor is intended for treatment of patients who have conductive or mixed hearing loss as a result of certain medical conditions such as bilateral atresia and chronic supportive otitis media, and for those who have Single-Sided Deafness (SSD) caused by a congenital condition, surgery, trauma, or disease.

Device Story

External sound processor; part of bone-anchored hearing system. Inputs: acoustic signals via microphone. Transformation: converts acoustic to electrical signals; drives mechanical transducer. Output: mechanical vibrations transmitted transcranially to cochlea via titanium implant/abutment. Used by patients with conductive/mixed hearing loss or SSD. Decoupled microphone/processor and actuator unit allow flexible wearing options to maximize gain and minimize feedback. Powered by rechargeable lithium-ion battery. Bypasses damaged outer/middle ear to provide direct stimulation to inner ear. Clinical benefit: improved sound access for patients with up to 65dB SNHL.

Clinical Evidence

Bench testing only. Performance testing compared subject device to predicate implant/abutment systems, including environmental, reliability, durability, electrical interface, and functional/performance testing. Results demonstrated functional equivalence to predicates.

Technological Characteristics

Medical grade plastics and metals. Bone conduction transducer. Rechargeable lithium-ion battery. Decoupled microphone/processor and actuator unit. Connects to titanium osseointegrated implant/abutment. Biocompatible materials.

Indications for Use

Indicated for patients of any age using Baha Softband/headband; patients aged 5+ for Baha osseointegrated implant system. Targets conductive/mixed hearing loss (bone-conduction threshold ≤ 65 dB HL) or unilateral sensorineural deafness (SSD) with normal hearing in contralateral ear (air-conduction threshold ≤ 20 dB HL). Bilateral fitting for symmetric moderate-to-severe conductive/mixed loss. Also indicated for patients who cannot/will not use AC CROS hearing aids.

Regulatory Classification

Identification

A bone-conduction hearing aid is a wearable sound-amplifying device intended to compensate for impaired hearing and that conducts sound to the inner ear through the skull. The non-implantable components of a bone-conduction hearing aid, such as the external sound processor, are subject to the requirements in § 801.422 of this chapter.

Predicate Devices

• Cordelle II Sound Processor (K150751)
• Baha 5 Sound Processor (K142907)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, with flowing lines representing hair or clothing.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

Cochlear Americas Mr. Tristan Manus Regulatory Affairs Specialist 13059 E. Peakview Ave. Centennial. CO 80111

Re: K153245

Trade/Device Name: Baha 5 Super Power Sound Processor Regulation Number: 21 CFR 874.3300 Regulation Name: Hearing Aid Regulatory Class: Class II Product Code: LXB Dated: January 29, 2016 Received: February 1, 2016

Dear Mr. Manus:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Kesia Alexander

for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

{2}------------------------------------------------

# 4. Indications for Use Statement

510(k) Number (if known): K153245

Device Name: Cochlear™ Baha® 5 SuperPower Sound Processor

Indications for Use:

The Cochlear™ Baha® 5 SuperPower Sound Processor is intended for the following patients and indications for use:

- Patients aged 5 and older o
- Patients who have a conductive or mixed hearing loss and can still benefit from sound ● amplification. The pure tone average bone-conduction hearing threshold (measured at 0.5, 1, 2, and 3kHz) should be better than or equal to 65 dB HL for use with the Baha 5 SuperPower Sound Processor.
- Bilateral fitting is intended for patients who meet the above criterion in both ears, with o bilaterally symmetric moderate to severe conductive or mixed hearing loss. Symmetrical bone-conduction thresholds are defined as less than a 10 dB average difference between ears (measure at 0.5, 1, 2, and 3 kHz), or less than a 15 dB difference at individual frequencies.
- Patients who suffer from unilateral sensorineural deafness in one was with normal ● hearing in the other ear (i.e. Single-sided deadness: SSD™). Normal hearing is defined as a pure tone average air-conduction hearing threshold (measure at 0.5, 1, 2, and 3 kHz) of better than or equal to 20 dB HL.
- Baha for SSD is also indicated for any patient who is indicated for an air-conduction ● contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.

| Prescription Use | X |
|-----------------------------|---|
| (Part 21 CFR 801 Subpart D) | |

AND/OR

| Over-The-Counter Use | |
|------------------------|--|
| (21 CFR 801 Subpart C) | |

(PLEASE FO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

{3}------------------------------------------------

## K153245

#### 510(K) Summary

A. Submitter Information Submitted by:

On behalf of the manufacturer

Contact:

#### B. Date Prepared

C. Device Class D. Device Name

Trade/Proprietary Name:

Common/Usual Name: Classification Name:

Classification Panel: Product Code: 510(k):

#### E. Predicate Device

(Primary) Trade/Proprietary Name: Common/Usual Name: Classification Name:

Classification Panel Product Code: 510(k):

(Secondarv) Trade/Proprietary Name: Common/Usual Name: Classification Name:

Classification Panel:

Cochlear Americas 13059 East Peakview Ave. Centennial, CO 80111

Cochlear Bone Anchored Solutions AB Konstruktionsvagen 14 SE-435 33 Molnlycke Sweden (Establishment Number 9616024)

Tristan Manus Regulatory Affairs Specialist II Cochlear Americas [e-mail] [phone] (o) [phone] (f)

November 6th 2015

### II

Cochlear™ Baha® 5 SuperPower Sound Processor Hearing Aid (Bone Conduction) Hearing Aid, Bone Conduction, Implanted 21 CFR 874.3300, Class II Ear, Nose, and Throat LXB K153245

Cordelle II Sound Processor Auditory Osseointegrated Implant Hearing Aid, Bone Conduction, Implanted 21 CFR 874.3300, Class II Ear, Nose, and Throat LXB K150751

Baha 5 Sound Processor Auditory Osseointegrated Implant Hearing Aid, Bone Conduction, Implanted 21 CFR 874.3300, Class II Ear, Nose, and Throat

{4}------------------------------------------------

Product Code: 510(k):

LXB K142907

#### F. Purpose of Submission

This submission is adding the Cochlear™ Baha® 5 SuperPower Sound Processor to the series of processors offered by Cochlear Bone Anchored Solutions (BAS). The Cochlear™ Baha® 5 SuperPower Sound Processor functions by combining the external sound processor with an abutment and a small titanium implant placed that is placed in the skull behind the ear through a simple surgical procedure. The sound processor transmits acoustic signals into electrical signals when then causes mechanical action in the transducer to transmit sound transcranially to the functioning auditory system.

#### G. Device Description

The technology base for the Baha implant was originally derived from the 1952 discovery by Dr. Per-Ingvar Branemark that titanium was biocompatible with bone, leading to the term "osseointegration"". The Branemark System, as it would later be known, formed the basis for the rapid development and widespread implementation of root form endosseous dental implants, now safely and effectively used by many hundreds of thousands of people worldwide. Root form dental implants share many characteristics with the Baha implant component including material, conformation, and surgical implantation procedures. Unlike hearing aids, the Baha hearing system utilizes a natural bone conduction pathway to send sound directly to a cochlea with residual functionality. The Baha system combines an external sound processor, in this application the Cochlear™ Baha® 5 SuperPower Sound Processor, with an abutment and small titanium implant placed into the bone through a simple surgical procedure. The implant subsequently forms an osseointegrated bond with the surrounding bone, allowing transmission of high-quality sound directly to the inner ear, bypassing a damaged outer or middle ear. The Baha system provides an alternate pathway for patients who may not benefit from wearing an air-conduction hearing aid. The changes introduced in this 510(k) are specific to the sound processor, not the abutment/implant or magnet. These changes culminate as the next generation Baha sound processor that provides recipients with moderately severe hearing loss (up to 65dB SNHL) access to sound. The Cochlear™ Baha® 5 SuperPower Sound Processor includes a decoupling of the microphone/processor and the actuator unit to allow various wearing options. The wearing options allow the recipient to achieve maximum gain while minimizing the likelihood of feedback. The design has been modified to incorporate a new rechargeable lithium-ion battery pack which provides the power needed for recipients with up to 65dB SNHL measured by pure tone average bone-conduction hearing thresholds at 0.5, 1, 2, and 3 kHz. This change does not modify the intended functionality or fundamental operating principles of the implant/abutment system.

#### H. Intended Use

The Cochlear™ Baha® 5 SuperPower Sound Processor is intended for treatment of patients who have conductive or mixed hearing loss as a result of certain medical conditions such as bilateral atresia and chronic supportive otitis media, and for those who have Single-Sided Deafness (SSD) caused by a congenital condition, surgery, trauma, or disease.

#### I. Indications for Use

The Cochlear™ Baha® 5 SuperPower Sound Processor has the following indications for use:

• Patients of any age for use with the Baha Softband or headband. Patients aged 5 and older for use with the Baha auditory osseointegrated implant system.

{5}------------------------------------------------

· Patients who have a conductive or mixed hearing loss and can still benefit from sound amplification. The pure tone average bone-conduction hearing threshold (measured at 0.5, 1, 2, and 3 kHz) should be better than or equal to 65 dB HL.

· Bilateral fitting is intended for patients who meet the criterion in both ears, with bilateral symmetric moderate to severe conductive or mixed hearing loss. Symmetrical bone-conduction thresholds are defined as less than a 10 dB average difference between ears (measured at 0.5, 1, 2, and 3 kHz), or less than a 15 dB difference at individual frequencies.

· Patients who suffer from unilateral sensorineural deafness in one ear with normal hearing in the other ear (i.e. Single-Sided Deafness; SSD). Normal hearing is defined as a pure tone average air-conduction hearing threshold (measured at 0.5, 1, 2, and 3 kHz) of better than or equal to 20 dB HL.

• Baha for SSD is also indicated for any patient who is indicated for an air-conduction contralateral routing of signals (AC CROS) hearing aid, but who for some reason cannot or will not use an AC CROS.

#### J. Technological Characteristics

The Cochlear™ Baha® 5 SuperPower Sound Processor has the same intended use, the same mechanical design, the same functional characteristics, the same fundamental operating principles, and is made of biocompatible materials as the predicate devices.

### K. Materials

The Cochlear™ Baha® 5 SuperPower Sound Processor is made of medical grade plastics and metals that have been shown to be biocompatible and safe for human use.

#### L. Performance Data

Performance testing was conducted to compare the Cochlear™ Baha® 5 SuperPower Sound Processor with the predicate implant / abutment systems. Substantial equivalence to the predicate device was accomplished through environmental testing, reliability and durability testing, electrical interface testing, and functional and performance testing. The results demonstrated the Cochlear™ Baha® 5 SuperPower Sound Processor is functionally equivalent to the predicate devices.

#### M. Conclusion

Based on the indications for use, technological characteristics, and substantial equivalence comparison to the predicate device, the Cochlear™ Baha® 5 SuperPower Sound Processor has been shown to be safe and effective for its intended use.